[go: up one dir, main page]

ECSP10010471A - Agonistas nicotínicos alfa 7 y antipsicóticos - Google Patents

Agonistas nicotínicos alfa 7 y antipsicóticos

Info

Publication number
ECSP10010471A
ECSP10010471A EC2010010471A ECSP10010471A ECSP10010471A EC SP10010471 A ECSP10010471 A EC SP10010471A EC 2010010471 A EC2010010471 A EC 2010010471A EC SP10010471 A ECSP10010471 A EC SP10010471A EC SP10010471 A ECSP10010471 A EC SP10010471A
Authority
EC
Ecuador
Prior art keywords
antipsychotic
alfa
nicotine agonists
nicotine
agonists
Prior art date
Application number
EC2010010471A
Other languages
English (en)
Inventor
Merouane Bencherif
Gregory J Gatto
Kristen G Jordan
Sharon R Letchworth
Terry Hauser
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of ECSP10010471A publication Critical patent/ECSP10010471A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente Invención se relaciona con una combinación sinérgica de un agonista nicotínico alfa 7 (?7) y un agente antipsicótico.
EC2010010471A 2008-02-13 2010-09-09 Agonistas nicotínicos alfa 7 y antipsicóticos ECSP10010471A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2828208P 2008-02-13 2008-02-13

Publications (1)

Publication Number Publication Date
ECSP10010471A true ECSP10010471A (es) 2010-10-30

Family

ID=40902222

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010471A ECSP10010471A (es) 2008-02-13 2010-09-09 Agonistas nicotínicos alfa 7 y antipsicóticos

Country Status (25)

Country Link
US (1) US20110059947A1 (es)
EP (2) EP2633868A1 (es)
JP (1) JP2011511845A (es)
KR (1) KR20100113163A (es)
CN (2) CN101977628A (es)
AU (1) AU2009214625A1 (es)
BR (1) BRPI0907570A2 (es)
CA (1) CA2715268A1 (es)
CO (1) CO6290706A2 (es)
CY (1) CY1114492T1 (es)
DK (1) DK2254598T3 (es)
EC (1) ECSP10010471A (es)
ES (1) ES2430622T3 (es)
HR (1) HRP20130749T1 (es)
IL (1) IL207389A0 (es)
MX (1) MX2010008875A (es)
NZ (1) NZ587312A (es)
PL (1) PL2254598T3 (es)
PT (1) PT2254598E (es)
RS (1) RS52941B (es)
RU (1) RU2481123C2 (es)
SG (1) SG188144A1 (es)
SI (1) SI2254598T1 (es)
WO (1) WO2009102962A2 (es)
ZA (1) ZA201005999B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
CN106074548A (zh) 2010-09-23 2016-11-09 艾伯维巴哈马有限公司 氮杂金刚烷衍生物的一水合物
SG191986A1 (en) * 2011-01-18 2013-08-30 Targacept Inc Treatment of cognitive dysfunction in schizophrenia
WO2012151136A1 (en) * 2011-05-03 2012-11-08 Merck Sharp & Dohme Corp. Aminomethyl biaryl benzotriazole derivatives
KR20150064098A (ko) * 2012-10-02 2015-06-10 다이닛본 스미토모 세이야꾸 가부시끼가이샤 이미다졸 유도체
JP6807094B2 (ja) * 2016-04-29 2021-01-06 国立大学法人秋田大学 クロザピン又はその誘導体の血中薬剤濃度上昇リスク判定方法及び薬剤投与量判定方法
CN110087641B (zh) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统
MX382195B (es) 2016-12-20 2025-03-13 Lts Lohmann Therapie Systeme Ag Sistema terapeutico transdermico que contiene asenapina
CN108727416B (zh) * 2017-04-20 2021-03-09 北京大学 三环杂芳香体系酰胺衍生物及其制备和用途
CN110799180A (zh) 2017-06-26 2020-02-14 罗曼治疗系统股份公司 含阿塞那平和硅氧烷丙烯酸杂化聚合物的经皮治疗系统
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
PL3810100T3 (pl) 2018-06-20 2025-05-12 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
CN117529475A (zh) 2021-01-08 2024-02-06 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的含脲或类似物的杂双环化合物及其化合物
EP4274660A1 (en) * 2021-01-08 2023-11-15 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
DE102022114269A1 (de) 2022-06-07 2023-12-07 Rational Aktiengesellschaft Gargerät mit einem Selbstreinigungssystem sowie ein Verfahren zum Ändern von Reinigungsparametern für das Gargerät

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5712270A (en) 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
ATE255888T1 (de) 1998-06-01 2003-12-15 Ortho Mcneil Pharm Inc Tetrahydronaphtalene verbindungen und deren verwendung zur behandlung von neurodegenerativen krankheiten
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
EA005002B1 (ru) * 1999-12-10 2004-10-28 Уайт НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-e]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ
DK1300407T4 (da) 2000-06-27 2011-09-05 S A L V A T Lab Sa Carbamater afledt af arylalkylaminer
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
WO2002016356A2 (en) 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
JP2004506735A (ja) 2000-08-18 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用キヌクリジン置換アリール化合物
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002017358A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
JP2004506734A (ja) 2000-08-21 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用のキヌクリド置換ヘテロアリール部分
US6554086B1 (en) * 2000-10-27 2003-04-29 Invacare Corporation Obstacle traversing wheelchair
HUP0303529A3 (en) 2000-12-22 2008-03-28 Almirall Ag New quinuclidine carbamate derivatives, process for their preparation and pharmaceutical compositions containing them and their use
CA2476624A1 (en) * 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
HRP20050494A2 (en) * 2002-12-06 2005-10-31 Pharmacia & Upjohn Company Llc Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compositions and preparations thereof
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
WO2004099202A1 (en) * 2003-05-05 2004-11-18 Pharmacia & Upjohn Company Llc Quinuclidines substituted bentodioxine carboxamides for the treatment of neurodegenerative diseases
US7309699B2 (en) * 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives
EP1699488A2 (en) * 2003-12-23 2006-09-13 Pfizer Products Incorporated Therapeutic combination for cognition enhancement and psychotic disorders
WO2006101745A2 (en) * 2005-03-18 2006-09-28 Abbott Laboratories Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions

Also Published As

Publication number Publication date
MX2010008875A (es) 2010-08-31
KR20100113163A (ko) 2010-10-20
RU2010137787A (ru) 2012-03-20
CA2715268A1 (en) 2009-08-20
CN103143023A (zh) 2013-06-12
PT2254598E (pt) 2013-10-16
EP2254598B1 (en) 2013-07-10
PL2254598T3 (pl) 2013-12-31
CY1114492T1 (el) 2016-10-05
ES2430622T3 (es) 2013-11-21
JP2011511845A (ja) 2011-04-14
IL207389A0 (en) 2010-12-30
WO2009102962A2 (en) 2009-08-20
US20110059947A1 (en) 2011-03-10
AU2009214625A1 (en) 2009-08-20
ZA201005999B (en) 2011-05-25
EP2254598A2 (en) 2010-12-01
RS52941B (sr) 2014-02-28
HRP20130749T1 (en) 2013-10-11
SG188144A1 (en) 2013-03-28
SI2254598T1 (sl) 2013-10-30
RU2481123C2 (ru) 2013-05-10
DK2254598T3 (da) 2013-07-29
HK1147954A1 (en) 2011-08-26
WO2009102962A3 (en) 2009-10-08
NZ587312A (en) 2011-12-22
CO6290706A2 (es) 2011-06-20
EP2633868A1 (en) 2013-09-04
BRPI0907570A2 (pt) 2019-09-24
CN101977628A (zh) 2011-02-16

Similar Documents

Publication Publication Date Title
ECSP10010471A (es) Agonistas nicotínicos alfa 7 y antipsicóticos
CO6210786A2 (es) Implemento de cuidado oral que alberga un agente de cuidado oral
CL2010001428A1 (es) Compuestos derivados de amidas y tioamidas heteroaromaticas; agente que contiene al menos uno de dichos compuestos; procedimiento para combatir parasitos; y uso de dichos compuestos.
NI201100068A (es) Combinación de una insulina y un agonista de glp-1.
MX338884B (es) Composiciones y metodos que comprenden variantes de proteasa.
UY33397A (es) Forma sólida de un naftaleno carboxamida
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
MY156511A (en) Compositions and devices
PH12013501312A1 (en) Fluid compositions comprising a structuring agent
GT200800123A (es) Compuestos mimeticos de lisina modificados
EP2176769A4 (en) DELEGATE INSTANT MESSAGING MEETINGS
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
HN2008000278A (es) Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta y su aplicacion terapeutica
MX2012008717A (es) Composiciones para el cuidado oral.
BRPI0906424A2 (pt) recurso de atributo de cache extraído e instrução consequente
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EP2252671A4 (en) AZEOTROPARTIC COMPOSITION OF 1,1,1-TRIFLUOR-3-CHLOROPROPENE AND DIMETHOXYMETHANE
HRP20151198T1 (xx) 5' trifosfat oligonukleotid s tupim krajem i njegove uporabe
AR067813A1 (es) Fenilendiaminas sustituidas como inhibidores de l ainteraccion entre mdm2 y p53
AR059444A1 (es) Composiciones ramnolipidicas y metodos de uso relacionados
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
CR20110227A (es) Partículas inhalables que comprenden tiotropio
CR20150275A (es) Composición de difenidol de liberación prolongada
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.